Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

NCT01045421 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

273

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Nonhematological Malignancies
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Metastatic Breast Cancer
Head and Neck Squamous Cell Carcinoma
Gastroesophageal Adenocarcinoma

Interventions

DRUG: MLN8237 (Alisertib)

Sponsor

Millennium Pharmaceuticals, Inc.